A multicentre registry observational study assessed lung involvement in a cohort of Still’s disease patients, affirming pleuritis as most common and that parenchymal lung inflammatory disease is very uncommon in both children and adults.

A total of 90 Still’s patients with lung involvement (mean age 36.3 years, 36% male) were identified among AIDA (AutoInflammatory Disease Alliance) Network Still’s Disease Registry. Among them, 13.3% were pediatric Stills patient. 

The majority (72%) of these had pleuritis; parenchymal disease was seen in 34%, ARDS in 9.5%, and pulmonary arterial hypertension in 2.3%.

Current concerns over Stills patients developing parenchymal lung involvement (possibly associated with biologic therapy) was investigated and no association was seen with the use of IL-1 or IL-6 inhibitors. Parenchymal lung patients had more sore throat, pericarditis, and higher values of systemic scores. 

While there are several pulmonary complications seen in patients with Still’s disease, pleuritis predominates.